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Background: Previous studies have been limited in reporting the association between chocolate consumption,
measured by interviewer-administered questionnaire or serum theobromine, a biomarker for cocoa, and risk of
preeclampsia, and have showed somewhat conflicting results.
Methods/Design: A systematic review of observational and experimental studies will be carried out. We will
examine PubMed, Embase, and the entire Cochrane Library. Studies of chocolate consumption compared or not
with placebo or low flavanol chocolate during pregnancy will be evaluated to investigate the effect of chocolate
consumption in pregnant women on the risk of preeclampsia or pregnancy-induced hypertension. Screening for
inclusion, data extraction, and quality assessment will be performed independently by two reviewers in consultation
with a third reviewer. Validity of the studies will be ascertained by using the Cochrane Collaboration’s tool. Relative
risk of preeclampsia will be the primary measure of treatment effect. Heterogeneity will be explored by subgroup
analysis according to confounding factors and bias.
Discussion: This systematic review will contribute to establish the current state of knowledge concerning the
possible association between chocolate consumption and prevention of preeclampsia. Furthermore, it will justify if
additional experimental trials are necessary to better evaluate the benefits of chocolate consumption on the risk of
preeclampsia.
Trial registration: This systematic review has been registered in the PROSPERO international prospective register of
systematic reviews. The registration number is: CRD42013005338.
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Preeclampsia, a syndrome defined by new-onset gestational
hypertension and proteinuria, originates in the placenta
and is characterized by generalized maternal dysfunction of
the endothelium. Endothelium dysfunction leads to clinical
symptoms of the mother [1,2]. Preeclampsia is one of the
most common medical disorders affecting pregnancy, with
potentially severe consequences for mother and child, par-
ticularly in developing countries [3]. It is estimated that 3%
to 8% of all pregnancies are affected by this complication.
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stated.60,000 deaths worldwide [4]. More than half of women
with preeclampsia will undergo Caesarean delivery. Pre-
eclampsia increases the risk of perinatal mortality by five-
fold, and is the primary cause of low birth weight in infants
[4]. Numerous studies have suggested that women who de-
velop preeclampsia have an increased risk of cardiovascular
disease later in life [5]. The cardiovascular manifestations of
preeclampsia share many characteristics and risk factors of
cardiovascular disease, including hypertension, endothelium
dysfunction, and oxidative stress [6,7].
Our recent data confirmed that endothelial function is
impaired in women who are at risk of preeclampsia, and
occurs before the development of the clinical syndrome [8].
There is strong evidence that maternal nitric oxide (NO)
deficiency plays a key role in the development of pre-
eclampsia [8]. Despite intensive research, preeclampsiaral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Mogollon et al. Systematic Reviews 2013, 2:114 Page 2 of 5
http://www.systematicreviewsjournal.com/content/2/1/114remains an idiopathic disease for which no effective
prophylactic measures are available to patients [3]. Thera-
peutic approaches focusing on up-regulating NO availabil-
ity may be useful targets in preeclampsia prevention.
Flavanols, the most common flavonoids in dark chocolate,
are potent antioxidants capable of inducing NO-dependent
vasodilatation. Two recent meta-analyses of randomized
controlled trials (RTCs) confirmed that flavanol-rich choc-
olate has a beneficial influence on endothelial function and
reduces systolic and diastolic blood pressure (BP) [9,10].
Theobromine, a major constituent of dark chocolate, also
possesses vasodilatation and relaxing smooth tissue proper-
ties [11].
As endothelial dysfunction is fundamental to the develop-
ment of preeclampsia, we therefore hypothesize that
flavanol-rich chocolate consumption reduces the risk of
preeclampsia via improvement of endothelial function in
pregnant women. Theobromine could account for, or con-
tribute to, enhancing the effect of flavanols. Indeed, re-
cently, a few observational and experimental studies have
been designed to evaluate the associations between choc-
olate consumption and/or theobromine, a biomarker of
cocoa intake with preeclampsia, but the results were con-
flicting [12-14]. The primary objective of this systematic re-
view is to investigate the effect of chocolate consumption
on preeclampsia risk in pregnant women using observa-
tional and experimental studies.
Methods
Methods to be used for this systematic review have been
elaborated as described by the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
statement and according to the recommendations of the
Cochrane Handbook for Systematic Reviews of Interven-
tions [15].
Criteria for considering studies for this review
Eligibility criteria
The study population, the intervention, and the outcome
will be used as criteria for eligibility of studies in this sys-
tematic review, reflecting the participants, interventions,
comparators, outcomes, and study design (PICOS) ap-
proach. All publication years, languages, and publication
statuses will be considered as report characteristics. No lan-
guage, publication date, or publication status restrictions
will be imposed.
Design of studies
In this systematic review, we will consider RCTs, well-
designed quasi-experimental (quasi-RCT) studies, con-
trolled before and after (CBA) studies, interrupted time
series (ITS) analyses, and observational studies (cohort,
case–control, and descriptive).Participants
Pregnant women will be considered in this systematic
review. Studies concerning all women without any age
restriction and with a live fetus will be eligible for par-
ticipation in this systematic review.
Interventions
Studies evaluating consumption of chocolate by either
interviewer-administered questionnaire or serum theo-
bromine will be considered in this systematic review. No
treatment period restrictions will be imposed. All studies
of chocolate consumption, regardless of type or dose of
chocolate, method of administration, assessment of
chocolate intake, and compared with low-flavanol choc-
olate or placebo or not, will be included.
Outcome
The main outcome will be risk of preeclampsia. Pre-
eclampsia will be defined according to the National
Heart, Lung, and Blood Institute (NHLBI) guidelines.
Risk of preeclampsia would be the ideal outcome meas-
ure, but it is likely that there may be observational
or interventional studies in pregnant women with
pregnancy-induced hypertension, which would be a
stage very close to preeclampsia. Therefore, in this re-
view, pregnancy-induced hypertension will be included
as a stand-in outcome if the studies measure this out-
come. We will include studies only if they measure these
outcomes.
Search method for identification of studies
Electronic searches of literature will be carried out from
their first available date without restriction. PubMed (jour-
nal articles from the 1950s onwards), Embase (records from
1974 onwards), and the entire Cochrane Library (2012,
issue 12) will be searched. Electronic databases will be
searched using a strategy combining selected thesaurus
MeSH terms and free text words including chocolate, pre-
eclampsia, pregnant women, and their synonyms [Annex 1
in Additional file 1] for potentially eligible studies. Using
the appropriate controlled vocabulary for the search strat-
egies, we will express them in different words as applicable
to the databases of PubMed [Annex 2 in Additional file 1],
Embase [Annex 3 in Additional file 1], and Cochrane
Library [Annex 4 in Additional file 1]. No language restric-
tions will be used.
Methods of the review
Screening
After searching all source databases, all the citations will
be exported into EndNote (Carlsbad, CA, USA) soft-
ware. The accumulated citations will be screened elec-
tronically using Microsoft Excel (Redmond, WA, USA).
The relevant articles will be obtained following removal
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searching. Two reviewers (JAM and CB) will independ-
ently assess titles and abstracts of pertinent articles
found according to the inclusion and exclusion criteria.
Previously, we developed a study selection sheet contain-
ing titles, abstracts, allocated inclusion status (‘e’, ex-
cluded; ‘i’, included; and ‘?’, unclear), and reasons for
exclusion. Judgment concerning inclusion will be made
individually and results compared. Divergences will be
discussed by two authors (JAM and CB) to resolve the
conflict; if no agreement is reached, a third reviewer
(SD) will be consulted to make a final decision. Finally,
full texts of all articles preliminarily identified as unclear
for inclusion based on title and abstract will be obtained
for a second screen.
Data extraction
The final set of studies for inclusion will be obtained after
review of full-text articles considered eligible by two re-
viewers (JAM and CB). Data will be extracted through a
standardized data compilation form [Annex 5 in Additional
file 1] inspired from the Cochrane Collaboration’s tool and
then cross-checked. Author names, sample sizes, and re-
sults of studies will be compared to avoid duplicates. This
form was pilot-tested on three studies to refine it conse-
quently. The data extraction form provides information on
qualitative aspects of studies.
Data will be extracted on: 1) publication source (such
as date of publication, design, geographical origin, con-
tact details, and location of research group); 2) eligibility
verification (such as study design, population, interven-
tion, outcome, and reasons for exclusion); 3) methods of
recruitment (such as duration of enrollment, inclusion
and exclusion criteria, diagnostic criteria of preeclamp-
sia, study size, and setting); 4) participant characteristics
(such as number included in the analysis, age range,
mean age, percentage of subjects per age interval, ethni-
city, level of education, socioeconomic status, parity,
percentage of women by body mass index (BMI) cat-
egory, smoking status, and percentage of women af-
fected by gestational diabetes); 5) characteristics of
intervention evaluated (such as type, timing of exposure,
method and technique of measurement, assessment of
chocolate consumption, total women by number of serv-
ings of chocolate consumed per week by trimester, and
assessment of consumption or median theobromine
concentration by trimester and theobromine cord con-
centration); and 6) information of the reported outcome
(such as outcome assessed, number of cases with pre-
eclampsia, total cases by quartiles of theobromine con-
centrations and categories of chocolate consumption by
trimester, measures of disease association (crude and ad-
justed) by quartiles of theobromine concentration, and
categories of chocolate consumption by trimester).Quality assessment
Two independent reviewers (JAM and CB) will evaluate
the risk of bias for eligible studies to ascertain their val-
idity. For this purpose, a standardized form [Annex 6 in
Additional file 1] was constructed inspired from the
Cochrane Collaboration’s tool for assessing risk of bias,
with reference to meta-analysis of observational studies
in epidemiology (MOOSE) [16], quality assessment
tool for systematic reviews of observational studies
(QUATSO) [17], and strengthening the reporting of ob-
servational studies in epidemiology (STROBE) [18] qual-
ity assessment tools.
The possibility of publication bias will be assessed by
evaluating a funnel plot of the studies log(RR) or log
(OR) against standard error for asymmetry, which can
result from the non-publication of small trials with nega-
tive results. Since graphical evaluation can be subjective,
an adjusted rank correlation test and a regression asym-
metry test will also be conducted as formal statistical
tests of publication bias. We acknowledge that other fac-
tors, such as differences in study quality or true study
heterogeneity, could produce asymmetry in funnel plots.
Summary of study results
The relative risk (RR) of preeclampsia will be the pri-
mary measure of treatment effect. If not reported in in-
cluded studies, the odds ratio (OR) will be considered
instead. Crude and adjusted RR and OR will be treated
separately; confounding factors will be noted for ad-
justed measures of association. In the case of data per-
mitting meta-analysis, the authors will be contacted to
obtain crude data in order to calculate RR. If databases
are not available, the RR or OR will be taken directly
from the publications.
Planned methods of analysis
Chocolate intake will be determined from food fre-
quency questionnaires, and categories of consumption
will be considered in the analysis. Serum theobromine, a
biomarker for cocoa, will also be considered in the ana-
lysis by interval of concentration. The specific categories
will be determined according to included studies.
Analysis of all studies meeting the inclusion criteria will
be carried out using Review Manager (RevMan) software
(version 5.2; The Nordic Cochrane Centre, Copenhagen).
For each study, n and the proportion of pregnant women
with preeclampsia according to the level of chocolate con-
sumption or control group will be entered into the soft-
ware. For randomized trials, a meta-analysis will be
performed if possible by category of intervention (chocolate
consumption) and the random effects model will be used.
For non-randomized studies, a meta-analysis will be carried
out by study design and potential confounding factors. The
potential confounding factors to be explored will be age,
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tational diabetes using directed acyclic graphs (DAGs) to
determine required adjustments, and subgroup analysis will
be used to explore heterogeneity.
Exploring heterogeneity
We hypothesize that the effect size may differ according to
the methodological quality of the studies, and we will ex-
plore the variability of study results (heterogeneity) before
conducting the analysis. Heterogeneity will be explored by
subgroup analysis according to confounding factors found.
If applicable, the robustness of the results will be tested by
different outcomes (if available) and type of chocolate.
Discussion
This systematic review will contribute to establish the
current state of knowledge concerning the possible associ-
ation between chocolate consumption and prevention of
preeclampsia, in light of the supporting evidence for the
pathophysiologically-related cardiovascular diseases. The
results of the systematic review will show the study,
population, and intervention characteristics related to
preeclampsia.
Furthermore, the systematic review will justify if add-
itional experimental trials are necessary to better evaluate
the benefits of chocolate consumption on the risk of pre-
eclampsia. If sufficient data can be extracted, we will con-
sider how the findings can be used to guide future studies
in this field and to support the hypothesis regarding the
preventive effect of chocolate consumption on the risk of
preeclampsia. Finally, we will identify sources of heterogen-
eity across the selected studies.
Additional file
Additional file 1: Annex 1. Search terms for search strategies. Annex 2.
Search strategy in PubMed. Annex 3. Search strategy in Embase.
Annex 4. Search strategy in the Cochrane Library. Annex 5. Data
extraction form. Annex 6. Assessment of quality.
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